R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The approval is supported by data from three pivotal clinical trials
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
Subscribe To Our Newsletter & Stay Updated
